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ABSTRACT
Background. The present study investigated relationships
between perioperative blood transfusion, postoperative
systemic inflammatory response, and outcomes following
surgery for colorectal cancer.
Methods. Data were recorded for patients (n = 544)
undergoing potentially curative, elective surgery for col-
orectal cancer at a single center between 2012 and 2017.
Transfusion history was obtained retrospectively from
electronic records. Associations between blood transfusion,
postoperative C-reactive protein (CRP), albumin, hemo-
globin, complications, cancer-specific survival and overall
survival (OS) were assessed using propensity score
matching (n =116).
Results. Of 544 patients, the majority were male (n =294,
54%), over 65 years of age (n =350, 64%), and with
colonic (n =347, 64%) node-negative disease (n =353,
65%). Eighty-six patients (16%) required perioperative
blood transfusion. In the unmatched cohort, blood trans-
fusion was associated with higher median postoperative
day (POD) 3 CRP {143 [interquartile range (IQR)
96–221 mg/L] vs. 120 (IQR 72–188 mg/L); p = 0.004},
lower median POD 3 albumin [24 (IQR 20–26 g/L) vs. 27
(IQR 24–30 g/L); p\ 0.001], more postoperative compli-
cations [odds ratio (OR) 3.28, 95% confidence interval (CI)
2.03–5.29] and poorer OS [hazard ratio (HR) 3.18, 95% CI
2.08–4.84]. In the propensity score matched cohort, blood
transfusion was similarly associated with higher median
POD 3 CRP [130 (IQR 93–196 mg/L) vs. 113 (IQR
66–173 mg/L); p = 0.046], lower median POD 3 albumin
[24 (IQR 20–26 g/L) vs. 26 (IQR 24–30 g/L); p\ 0.001],
more postoperative complications (OR 2.91, 95% CI
1.36–6.20) and poorer OS (HR 2.38, 95% CI 0.99–5.73).
Conclusions. Perioperative blood transfusion was associ-
ated with postoperative inflammation, complications, and
poorer survival in patients undergoing colorectal cancer
surgery, with and without propensity score techniques.
A significant proportion of patients undergoing surgery
for colorectal cancer require allogeneic blood transfusion
in the perioperative period.1 Such transfusions are associ-
ated with infective postoperative complications and
anastomotic leak.2,3 They are also associated with disease
recurrence,3,4 and this effect is even greater in the presence
of infective complications.5 Therefore, it has long been
hypothesized that allogeneic blood transfusion might
impair the host adaptive immune response to both patho-
gens and circulating or micrometastatic tumor cells.6
There is increasing evidence that an exaggerated post-
operative systemic inflammatory response following
surgery for colorectal cancer is associated with postoper-
ative complications and long-term survival.7 Furthermore,
there is some observational evidence that modulation of
this response can improve both short-8, and long-term
outcomes.9 It may be that perioperative blood transfusion
and postoperative complications have a negative impact on
oncologic outcomes via a common pathway, the systemic
inflammatory response.10
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The aim of this study was to examine the association
between perioperative blood transfusion and the magnitude
of postoperative systemic inflammatory response, in par-
ticular C-reactive protein (CRP) and albumin, which have
been reported to be reliable indicators of the magnitude of
surgical injury.11 Furthermore, the study aimed to examine
the impact of blood transfusion on the development of
postoperative complications and long-term outcomes fol-
lowing surgery for colorectal cancer.
MATERIALS AND METHODS
Patients
This observational study was a retrospective analysis of
a prospectively collected and maintained cohort. Inclusion
criteria were patients from a single surgical unit with col-
orectal cancer who underwent surgery with curative intent
between January 2012 and June 2017. Exclusion criteria
were emergency surgery, palliative presentation, pre-ex-
isting systemic inflammatory comorbidity, hematological
malignancy, and long-term steroids.
Prior to and following surgery, all cases were discussed
at a multidisciplinary colorectal oncology meeting.
Antimicrobial and venous thromboembolism prophylaxis
was administered at the time of surgery. Perioperative care
was standardized using an ‘enhanced recovery’ protocol. A
proportion of patients received postoperative nausea and
vomiting prophylaxis in the form of intravenous dexam-
ethasone during surgery, at the discretion of the consultant
anesthetist.8,12
During the study period, there was no formal perioper-
ative blood transfusion protocol. As reported previously,13
between June 2016 and June 2017 a preoperative iron
replacement protocol was in place for the relatively small
number of patients found to have true iron-deficient
anemia.
On each day from surgery to discharge, patients had a
bedside review by the responsible operating team, and
blood samples were drawn for CRP and albumin. The
patient’s surgical team arranged further investigation, and/
or intervention, based on clinical assessment and these
blood results.
METHODS
Patient data were recorded securely and anonymized
prior to analysis. The data collected included factors pre-
viously reported to be associated with the postoperative
systemic inflammatory response, including modified Glas-
gow Prognostic Score (mGPS), laparoscopic resection,
body mass index (BMI) and American Society of
Anesthesiologists (ASA) score.14 TNM stage (TNM, 5th ed
American Joint Committee on Cancer [AJCC]) and
pathological features were recorded, as were demographic
variables.
Hematological parameters were recorded from full
blood count samples taken within 2 weeks prior to surgery.
Patients were classified as having anemia based on World
Health Organization (WHO) guidelines for males, i.e.
hemoglobin (Hb)\ 130 mg/L, and females, i.e. Hb\
120 mg/L.15 Furthermore, anemic patients were classified
as having microcytic anemia with mean corpuscular vol-
ume (MCV)\ 80 f/L, normocytic anemia with MCV
80–100 f/L, or macrocytic anemia with MCV[ 100 f/L.
Retrospective linkage with the blood transfusion elec-
tronic database allowed recording of the transfusion of
packed red cells (PRCs), number of units transfused, and
the time given. Perioperative blood transfusion was defined
as any transfusion of PRCs from 30 days prior to 30 days
following surgery. All units of PRCs were leucodepleted
following screening for blood-borne viruses (HIV, Human
T-lymphotropic virus, and hepatitis B and C), malaria, and
syphilis. All PRCs were stored between 2 and 6 C and
used within 35 days of donation.
Serum concentrations of CRP (mg/L) were measured
using an autoanalyzer (Architect; Abbot Diagnostics,
Maidenhead, UK) with a lower detectable limit of 0.2 mg/
L, as was serum albumin (normal range 35–50 g/L). The
mGPS was calculated in patients for whom preoperative
serum CRP and albumin were available.16 On days 3 and 4,
after surgery for those patients with available CRP and
albumin, the validated postoperative Glasgow Prognostic
Score (poGPS) was calculated.7
If complications occurred between surgery and first
clinic follow-up, they were recorded according to the most
severe, using the Clavien–Dindo grade,17 and type. Infec-
tive complications were categorized as described
previously.18 Superficial surgical site infection was defined
as the presence of pus either drained from the wound or
discharging spontaneously. Deep surgical site infection
was diagnosed either on imaging, radiological drainage, or
surgical drainage of intra-abdominal pus, while anasto-
motic leak was diagnosed at laparotomy or on cross-
sectional imaging. Lower respiratory tract infection was
defined as consolidation on chest radiograph or computed
tomography (CT) scan associated with pyrexia and
requiring antibiotic treatment, whereas septicemia was
defined as a combination of the systemic inflammatory
response syndrome and positive blood culture. Urinary
tract- or catheter-related infection was only diagnosed in
the presence of the systemic inflammatory response syn-
drome and positive urine culture.
The study was approved by the West of Scotland
Research Ethics Committee, Glasgow.
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Statistical Analysis
In the unmatched cohort, categorical data were com-
pared using the Chi square test and Chi square for linear
association where appropriate. Postoperative CRP, albu-
min, and Hb were non-normal, presented as medians and
ranges, and compared using the Mann–Whitney U test. The
magnitude of CRP, albumin, and Hb by each postoperative
day (POD) was displayed graphically as 95% confidence
intervals of the median.
Following exclusion of deaths within 30 days of surgery
or during the index admission, cancer-specific survival
(CSS) was defined as the time from the day of resection to
the day of colorectal cancer death. Overall survival (OS)
was defined as the time from the day of resection to that of
all-cause death. Survival was presented as a cumulative
proportion of patients alive at 5 years following surgery
and assessed using the log-rank test.
Multivariate logistic regression generated propensity
scores, predicting the probability of having received a
perioperative transfusion, based on variables associated
with the postoperative systemic inflammatory response or
complications14; age, sex, BMI, ASA, mGPS, tumor site,
TNM stage, neojuvant chemoradiotherapy, surgical
approach (open or laparoscopic), administration of intra-
operative dexamethasone, and preoperative anemia.
Patients who received a perioperative blood transfusion
were then matched 1:1 with a patient who did not, using the
closest propensity score on the logit scale (calliper\ 0.05,
order of match selection randomized, no replacement).
Categorical data were compared using McNemar’s test,
while continuous data were compared using the related
samples Wilcoxon signed-rank test. The appropriateness of
the propensity score matching was assessed visually by the
frequency of propensity scores in each group before and
after matching.
Sensitivity analyses compared the effect size of peri-
operative blood transfusion in relation to CRP
concentrations on postoperative day 3 using linear regres-
sion, postoperative complications using binary logistic
regression presented as odd ratios (OR) and 95% CI, and
overall survival using Cox regression presented as hazard
ratios (HR) and 95% CI, between the unmatched cohort,
propensity score matched cohort, and using propensity
score regression.
Factors associated with postoperative complications and
OS among patients receiving perioperative blood transfu-
sion were examined using multivariate binary logistic
regression and multivariate Cox regression, respectively.
Variables associated with outcomes at a univariate level of
p\ 0.1 were entered into a backward conditional model,
where p\ 0.05 was considered statistically significant.
In all tests, a two-sided p value\ 0.05 was considered
statistically significant. Propensity scoring matching and all
statistical analyses were performed using IBM SPSS ver-
sion 24 for Windows (IBM Corporation, Armonk, NY,
USA).
RESULTS
Patients
Overall, 544 patients were included, the majority of
whom were male (n =294, 54%), over 65 years of age
(n =350, 64%), and with colonic (n =347, 64%) and node-
negative disease (n =353, 65%). One hundred and ninety
patients (35%) were anemic prior to surgery, of whom 42
(8%) had microcytic anemia and 148 (27%) had normo-
cytic anemia. Eighty-six patients (16%) required allogeneic
blood transfusion within the perioperative period, with 9
patients (2%) receiving a preoperative blood transfusion,
67 (12%) receiving an intraoperative or postoperative
blood transfusion, and 10 (2%) receiving a transfusion at
multiple time points. Two hundred and seven patients
(38%) experienced a complication, of which 130 (24%)
were infective, with 23 (4%) anastomotic leaks, and 53
(10%) were Clavien–Dindo grade 3–5. There were 7 (1%)
deaths within 30 days of surgery. During the follow-up
period, 87 patients died (16%), 52 (10%) cases of which
were due to colorectal cancer. The median follow-up of
those alive at the time of censoring was 43 months (range
12–77).
Perioperative Blood Transfusion in the Unmatched
Cohort
In the unmatched cohort (Table 1), perioperative blood
transfusion was associated with increasing age (p = 0.038),
lower BMI (p = 0.028), higher ASA grade (p = 0.001),
mGPS of 2 (p\ 0.001), open surgery (p\ 0.001), and
non-administration of dexamethasone (p\ 0.001). Patients
who received a perioperative blood transfusion had a sig-
nificantly lower preoperative Hb (p\ 0.001), and a
significantly higher proportion had normocytic anemia
(p\ 0.001).
Patients who received a perioperative blood transfusion
had a significantly lower Hb on PODs 1–5 (Fig. 1a), a
significantly higher CRP on PODs 1–3 (Fig. 1c), and a
significantly lower albumin on PODs 1–5 (Fig. 1e). A
higher proportion of patients who received a perioperative
blood transfusion had a poGPS of 2 on PODs 3 (32% vs.
15%; p = 0.004) and 4 (29% vs. 12%; p = 0.010).
Patients who received a perioperative blood transfusion
had a significantly higher rate of postoperative
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TABLE 1 Clinicopathological characteristics of patients undergoing elective, open surgery for colorectal cancer receiving any perioperative
blood transfusion—unmatched cohort
Characteristics All [n = 544] No transfusion [n = 458] Transfusion [n = 86] p value
Clinicopathological
Age, years (\ 65/65–74/C 75) 194/208/142 168/180/110 26/28/32 0.038
Sex (male/female) 294/248 253/203 41/45 0.196
BMI (\ 20/20–25/26–30/[ 30 kg/m2) 33/169/168/164 23/142/141/145 10/27/27/19 0.028
ASA (1/2/3/4) 131/234/149/14 117/204/119/8 14/30/30/6 0.001
Iron infusion (yes/no) 19/531 18/440 1/85 0.336
Approach (laparoscopic/open) 269/263 246/200 23/63 \ 0.001
Perioperative dexamethasone (yes/no) 334/138 302/104 32/34 \ 0.001
Tumor site (colon/rectum) 347/196 285/173 62/23 0.065
Operation duration, mins [median (IQR)]
Colonic 180 (131–252) 181 (135–240) 173 (120–207) 0.107
Rectal 275 (210–335) 275 (209–335) 283 (228–409) 0.811
TNM stage (0/I/II/III) 13/127/213/183 10/117/174/152 3/10/39/31 0.132
Neoadjuvant treatment (yes/no) 78/458 62/391 16/67 0.180
Hematological
Preoperative Hb, g/L [median (IQR)] 131 (118–144) 133 (124–146) 106 (98–121) \ 0.001
Preoperative anemia (no/microcytic/normocytic)a 354/42/148 333/20/105 21/22/43 \ 0.001
POD 1 Hb, g/L [median (IQR)] 110 (98–123) 113 (103–125) 94 (87–101) \ 0.001
POD 2 Hb, g/L [median(IQR)] 107 (97–120) 110 (100–123) 90 (82–101) \ 0.001
POD 3 Hb, g/L [median (IQR)] 108 (98–121) 111 (101–124) 95 (90–101) \ 0.001
POD 4 Hb, g/L [median (IQR)] 110 (99–122) 114 (103–125) 96 (92–105) \ 0.001
POD 5 Hb, g/L [median (IQR)] 111 (99–125) 114 (103–127) 98 (92–107) \ 0.001
Systemic inflammation
Preoperative mGPS (0/1/2)b 399/42/56 345/37/37 54/5/19 \ 0.001
POD 1 CRP, mg/L [median (IQR)] 83 (55–116) 80 (52–112) 101 (72–138) \ 0.001
POD 2 CRP, mg/L [median (IQR)] 132 (82–197) 127 (79–191) 164 (117–225) \ 0.001
POD 3 CRP, mg/L [median (IQR)] 127 (76–192) 120 (72–188) 143 (96–221) 0.004
POD 4 CRP, mg/L [median (IQR)] 101 (64–172) 100 (63–167) 115 (72–239) 0.050
POD 5 CRP, mg/L [median (IQR)] 86 (51–158) 83 (49–149) 107 (55–232) 0.051
POD 1 albumin, g/L [median (IQR)] 28 (25–31) 28 (25–31) 24 (21–26) \ 0.001
POD 2 albumin, g/L [median (IQR)] 27 (24–31) 28 (25–31) 23(21–26) \ 0.001
POD 3 albumin, g/L [median (IQR)] 26 (24–30) 27 (24–30) 24 (20–26) \ 0.001
POD 4 albumin, g/L [median (IQR)] 26 (23–29) 27 (24–30) 23 (20–26) \ 0.001
POD 5 albumin, g/L [median (IQR)] 26 (23–29) 27 (24–30) 23 (19–25) \ 0.001
poGPS 3 (0/1/2)c 304/115/88 262/102/62 42/13/26 0.004
poGPS 4 (0/1/2)c 300/62/64 249/58/41 51/4/23 0.010
Short-term outcomes
Any complication (yes/no) 207/332 154/301 53/31 \ 0.001
Infective complication (yes/no) 130/409 91/364 39/45 \ 0.001
Anastomotic leak (yes/no) 23/516 8/447 15/69 \ 0.001
Clavien–Dindo grade (0–2/3–5) 484/53 429/24 55/29 \ 0.001
30-day mortality (yes/no) 7/532 5/449 1/83 0.451
Length of stay, days [median (IQR)] 7 (5–12) 7 (5–10) 12 (7–19) \ 0.001
Long-term outcomes
Adjuvant treatment (yes/no) 165/295 146/240 19/55 0.048
5-year CSS (%) 86 89 68 \ 0.001
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complications (63% vs. 34%; p\ 0.001), infective com-
plications (46% vs. 20%; p\ 0.001), anastomotic leak
(18% vs. 2%; p\ 0.001), and Clavien–Dindo grade 3–5
complications (35% vs. 5%; p\ 0.001), as well as a longer
median length of stay (12 vs. 7 days; p\ 0.001).
Perioperative blood transfusion was significantly asso-
ciated with poorer 5-year CSS (68% vs. 89%; p\ 0.001)
and poorer 5-year OS (59% vs. 82%; p\ 0.001).
Perioperative Blood Transfusion in the Propensity
Score Matched Cohort
Propensity scores could not be assigned to 121 patients
due to missing covariate data, leaving 423 patients with
propensity scores, of whom 62 had received a perioperative
blood transfusion and 361 had not (Fig. 2a). One hundred
and sixteen patients were matched (58 in each group) based
on their propensity scores, with a subsequent improvement
in the balance of their distribution (Fig. 2b).
In the propensity score matched cohort (Table 2),
patients receiving a perioperative blood transfusion had
significantly lower Hb on POD 2, but at no other time point
(Fig. 1b). Patients receiving a perioperative blood trans-
fusion had a significantly higher CRP on PODs 1–4
(Fig. 1d), and significantly lower albumin on PODs 1–5
(Fig. 1f). A higher proportion of patients who received a
perioperative blood transfusion had a poGPS of 2 on POD
3 (28% vs. 13%; p = 0.031), but not on POD 4 (p = 0.344).
Patients who received a perioperative blood transfusion
had a significantly higher rate of postoperative complica-
tions (59% vs. 33%; p = 0.017), anastomotic leak (15% vs.
2%; p = 0.021), and Clavien–Dindo grade 3–5 complica-
tions (34% vs. 5%; p\ 0.001), as well as a longer median
length of stay (11 vs. 7 days; p = 0.011).
There was no significant difference in 5-year CSS (%) or
5-year OS (%) between the propensity score matched
groups.
Sensitivity Analyses
A similarly statistically significant association was
found at linear regression with CRP as the dependent
variable and blood transfusion as the explanatory variable,
in the unmatched cohort, when patients with major com-
plications (Clavien–Dindo grades 3–5) were excluded from
the analysis, when using propensity score regression, and in
the propensity score matched cohort (Table 3). The same
was found using binary logistic regression with postoper-
ative complication as the outcome variable, and Cox
regression with OS as the outcome variable.
Factors Associated with Poorer Outcomes Among
Patients Receiving Perioperative Blood Transfusion
When those patients who received a perioperative blood
transfusion (n = 86) were examined (Table 4), at univari-
ate binary logistic regression, surgery for rectal cancer
(p = 0.050), and increasing day 3 poGPS (p = 0.007) were
associated with postoperative complications. At multi-
variate analysis, only day 3 poGPS remained significantly
associated with postoperative complications (OR 2.47,
95% CI 1.93–3.15; p\ 0.001).
At univariate Cox regression, increasing ASA
(p = 0.001), T stage (p = 0.029), and mGPS (p = 0.007)
were significantly associated with poorer OS. At multi-
variate analysis, ASA (HR 1.96, 95% CI 1.16–3.33;
p = 0.012) and mGPS (HR 1.69, 95% CI 1.08–2.62;
p = 0.020) remained independently associated with OS.
DISCUSSION
The results of the present study report a significant
association between perioperative blood transfusion, an
exaggerated postoperative systemic inflammatory
response, postoperative complications and survival fol-
lowing surgery for colorectal cancer. This remained the
case even after propensity score matching for variables
TABLE 1 continued
Characteristics All [n = 544] No transfusion [n = 458] Transfusion [n = 86] p value
5-year OS (%) 79 82 59 \ 0.001
Data are expressed as n unless otherwise specified
ASA American Society of Anesthesiologists grade, BMI body mass index, Hb Hemoglobin, CRP C-reactive protein, OS overall survival, CSS
cancer-specific survival, POD postoperative day, IQR interquartile range, mGPS modified Glasgow Prognostic Score, poGPS postoperative
Glasgow Prognostic Score, MCV mean corpuscular volume
aMales = Hb\ 130 g/L, females = Hb\ 120 g/L; microcytic = anemia and MCV\ 80 fL; normocytic = anemia and MCV 80–100 fL
b0 = CRP\ 10 mg/L; 1 = CRP C 10 mg/L and albumin C 35 g/L; 2 = CRP C 10 mg/L and albumin\ 35 g/L
c0 = CRP\ 150 mg/L; 1 = CRP C 150 mg/L and albumin C 25 g/L; 2 = CRP C 150 mg/L and albumin\ 25 g/L
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FIG. 1 Line charts comparing patients who did (yellow lines) and
did not (blue lines) receive perioperative blood transfusions with
regard to postoperative median hemoglobin concentrations (g/L) in
the a unmatched and b propensity score matched cohorts,
postoperative median CRP concentrations (mg/L) in the
c unmatched and d propensity score matched cohorts, and
postoperative median albumin concentrations (g/L) in the
e unmatched and f propensity score matched cohorts. Bars represent
95% confidence intervals. preop preoperative, CRP C-reactive protein
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known to be associated with blood transfusion, postoper-
ative systemic inflammatory response, and postoperative
complications. Although blood transfusion is recognized to
be associated with healthcare-related serious infection19
and short- and long-term outcomes following colorectal
cancer resection, this study lends evidence to one of the
proposed mechanisms—modulation of the host immune
response to surgery.
There is increasing evidence that an exaggerated post-
operative systemic inflammatory response is associated
with postoperative complications and poorer oncologic
outcomes in patients with gastrointestinal cancer.20–22 It is
hypothesized that the primarily innate immune response to
the trauma of surgery leads to relative suppression of
adaptive responses.10,23 The reduced efficacy of this useful
anticancer response, coupled with the pro-metastatic nature
of the innate cellular, cytokine and neurohormonal surgical
response, may increase the risk of recurrence.24 Further-
more, it has been observed that modulation of the
postoperative systemic inflammatory response with peri-
operative corticosteroids is associated with fewer
postoperative complications and improved survival; how-
ever, these findings are yet to be confirmed in prospective
trials.8,9
Allogeneic blood transfusion in the perioperative period
is widely thought to be negatively associated with short-
term postoperative outcomes and survival in patients
undergoing surgery for cancer, with an older Cochrane
review,4 a recent large propensity score matched study of
over 4000 patients,25 and a very recent comprehensive
meta-analysis3 reporting this to be the case. However, two
propensity score matched cohorts from a single group of
researchers found no negative impact on survival in colon26
or rectal cancer,27 and a smaller recent observational study
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TABLE 2 Clinicopathological characteristics of patients undergoing elective, open surgery for colorectal cancer receiving any perioperative
blood transfusion—propensity score matched cohort
Characteristics All [n = 116] No transfusion [n = 58] Transfusion [n = 58] p value
Clinicopathological
Age, years (\ 65/65–74/C 75) 35/39/42 16/22/20 19/17/22 –
Sex (male/female) 62/54 32/26 30/28 –
BMI (\ 20/20–25/26–30/[ 30 kg/m2) 10/35/40/31 5/20/17/16 5/15/23/15 –
ASA (1/2/3/4) 16/49/48/3 7/26/24/1 9/23/24/2 –
Iron infusion (yes/no) 8/108 8/50 0/58 –
Approach (laparoscopic/open) 44/72 25/33 19/39 –
Operation duration, min [median (IQR)]
Colonic 164 (120–204) 150 (120–193) 171 (130–210) –
Rectal 292 (240–409) 293 (240–360) 292 (251–409) –
Perioperative dexamethasone (yes/no) 72/44 42/16 30/28 –
Tumor site (colon/rectum) 89/27 48/10 41/17 –
TNM stage (0/I/II/III) 4/15/52/45 1/8/26/23 3/7/26/22 –
Neoadjuvant treatment (yes/no) 19/95 9/48 10/47 –
Hematological
Preoperative Hb, g/L [median (IQR)] 109 (101–118) 110 (105–117) 106 (98–128) –
Preoperative anemia (no/microcytic/normocytic)a 20/28/64/4 2/15/38/3 18/13/26/1 –
POD 1 Hb, g/L [median (IQR)] 95 (88–103) 97 (91–104) 93 (86–100) 0.063
POD 2 Hb, g/L [median (IQR)] 93 (84–101) 96 (90–101) 89 (82–101) 0.033
POD 3 Hb, g/L [median (IQR)] 96 (90–104) 98 (89–105) 95 (90–103) 0.443
POD 4 Hb, g/L [median (IQR)] 97 (93–106) 98 (94–107) 96 (92–106) 0.597
POD 5 Hb, g/L [median (IQR) 99 (93–107) 99 (95–108) 100 (92–107) 0.820
Systemic inflammation
Preoperative mGPS (0/1/2)b 8/82/26 43/4/11 39/4/15 –
POD 1 CRP, mg/L [median(IQR)] 87 (64–117) 83 (55–112) 96 (71–126) 0.024
POD 2 CRP, mg/L [median(IQR)] 143 (86–198) 122 (78–183) 153 (117–201) 0.011
POD 3 CRP, mg/L [median (IQR)] 126 (81–177) 113 (66–173) 130 (93–196) 0.046
POD 4 CRP, mg/L [median (IQR)] 97 (59–174) 93 (50–157) 99 (63–239) 0.029
POD 5 CRP, mg/L [median (IQR)] 81 (41–144) 74 (42–118) 96 (40–208) 0.264
POD 1 albumin, g/L [median (IQR)] 26 (23–29) 28 (25–31) 24 (21–26) \ 0.001
POD 2 albumin, g/L [median (IQR)] 25 (23–29) 28 (24–31) 23 (21–26) \ 0.001
POD 3 albumin, g/L [median(IQR)] 25 (22–27) 26 (24–30) 24 (20–26) \ 0.001
POD 4 albumin, g/L [median (IQR)] 24 (22–27) 26 (23–29) 23 (21–26) 0.025
POD 5 albumin, g/L [median (IQR)] 24 (22–28) 27 (24–29) 23 (19–25) 0.003
poGPS 3 (0/1/2)c 66/21/22 35/13/7 31/8/15 0.031
poGPS 4 (0/1//2)c 69/8/20 32/6/7 37/2/13 0.344
Short-term outcomes
Any complication (yes/no) 53/63 19/39 34/24 0.017
Infective complication (yes/no) 33/83 11/47 22/36 0.061
Anastomotic leak (yes/no) 10/106 1/57 9/49 0.021
Clavien–Dindo grade (0–2/3–5) 23/93 55/3 38/20 \ 0.001
30-day mortality (yes/no) 1/115 0/58 1/57 –
Length of stay, days [median (IQR)] 8 (6–13) 7 (5–12) 11 (6–16) 0.011
Long-term outcomes
Adjuvant treatment (yes/no) 32/63 19/28 13/35 0.732
5-year CSS (%) 78 90 70 0.199
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found no independent impact of blood transfusion on col-
orectal cancer recurrence when corrected for preoperative
anemia.28 It is unclear why more recent studies tend to
report no impact on survival. It may be that modern blood
donation, processing, and transfusion guidelines lead to a
lower negative risk profile, or it may relate to the analyses
used by the reporting groups. With this in mind, the present
study included preoperative anemia as a matching variable
along with a wider variety of other perioperative variables,
and the results are in favor of a negative impact on both
short- and long-term outcomes. Given the association
between perioperative blood transfusion and postoperative
systemic inflammatory response, it is possible that the
contribution of blood transfusion to postoperative
immunologic dissonance is the mechanism by which such
outcomes are affected.29 Indeed, this would be in keeping
with older evidence reporting even poorer outcomes in
patients who both received a perioperative blood transfu-
sion and experienced a postoperative infective
complication.30,31
In the propensity score matched cohort, perioperative
blood transfusion was not associated with sustained sig-
nificant differences in postoperative Hb. This might
suggest that despite the transfusion of PRCs achieving the
aim of restoring the oxygen-carrying capacity of the blood,
the impact on the host immune system still leads to poorer
outcome.
Alternatively, it is possible that more advanced and
bulky tumors lead to longer and more difficult surgery,
generating a greater inflammatory response, while also
being associated with an increased transfusion requirement
and a greater likelihood of morbidity and mortality.
Although the propensity score matching process in the
present study aimed to correct for most of these con-
founders, its retrospective nature prevents us from making
any causal inference between transfusion and postoperative
inflammatory response.
The present study has a number of limitations. Its ret-
rospective nature leads to missing data, and the use of
propensity score matching, although designed to reduce
confounding, can introduce bias in parameters that have not
been recorded or are unknown. Furthermore, its use leads
to loss of statistical power. The lack of a formal blood
transfusion protocol during the study period means that
some patients with preoperative anemia did not receive a
perioperative blood transfusion, whereas some patients
who were not anemic did, presumably due to intraoperative
blood loss or other factors. Compounding this, the small
numbers of transfused patients prevented meaningful
TABLE 2 continued
Characteristics All [n = 116] No transfusion [n = 58] Transfusion [n = 58] p value
5-year OS (%) 72 85 63 0.094
Data are expressed as n unless otherwise specified
ASA American Society of Anesthesiologists grade, BMI body mass index, Hb hemoglobin, CRP C-reactive protein, OS overall survival, CSS
cancer-specific survival, POD postoperative day, IQR interquartile range, mGPS modified Glasgow Prognostic Score, poGPS postoperative
Glasgow Prognostic Score, MCV mean corpuscular volume
aMales = Hb\ 130 g/L, females =\ 120 g/L; microcytic = anemia and MCV\ 80 fL; normocytic = anemia and MCV 80–100 fL
b0 = CRP\ 10 mg/L; 1 = CRP C 10 mg/L and albumin C 35 g/L; 2 = CRP C 10 mg/L and albumin\ 35 g/L)
c0 = CRP\ 150 mg/L; 1 = CRP C 150 mg/L and albumin C 25 g/L; 2 = CRP C 150 mg/L and albumin\ 25 g/L
TABLE 3 Sensitivity analysis: linear regression coefficients of
postoperative day 3 C-reactive protein concentrations, odds ratios of
postoperative complications, and hazard ratios of all-cause mortality
with respect to perioperative blood transfusion across the propensity
score methods
Model n POD 3 CRP [B (95% CI)] Complication [OR (95% CI)] Overall survival [HR (95% CI)]
Unadjusted 544 34 (15–54) 3.28 (2.03–5.29) 3.18 (2.08–4.84)
Excluding CD grade 3–5 complications 484 28 (6–51) – 2.76 (1.65–4.66)
Propensity score regression 423 31 (8–54) 2.07 (1.14–3.77) 1.88 (1.04–3.41)
Propensity score matched 116 34 (3–64) 2.91 (1.36–6.20) 2.38 (0.99–5.73)
B linear regression coefficient, POD postoperative day, CD Clavien–Dindo, CRP C-reactive protein, OR odds ratio, HR hazard ratio, CI
confidence interval
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subgroup analysis of transfusion timing. Estimated blood
loss was recorded very poorly, preventing this important
variable from being included in the analysis. Despite this,
the similar effect sizes found at sensitivity analysis suggest
internal validity to the findings.
CONCLUSIONS
The present study reports a significant association
between perioperative blood transfusion, the postoperative
systemic inflammatory response, complications and sur-
vival following surgery for colorectal cancer. Furthermore,
in those who received a blood transfusion, an exaggerated
perioperative innate systemic inflammatory response
appeared to compound the negative effects on short- and
long-term outcomes. Although the described relationship
between blood transfusion and poorer outcomes is not new,
the present study suggests a possible mechanism, i.e.
modulation of the postoperative systemic inflammatory
response.
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TABLE 4 Factors associated with postoperative complications and overall survival in patients who received a perioperative blood transfusion
Postoperative complications variable Univariate OR (95% CI) p value Multivariate OR (95% CI) p value
Age 0.85 (0.50–1.46) 0.557 – –
Male sex 1.29 (0.53–3.09) 0.575 – –
BMI 0.85 (0.53–1.35) 0.483 – –
ASA 1.02 (0.61–1.72) 0.928 – –
Laparoscopic 0.70 (0.26–1.84) 0.468 – –
Dexamethasone 0.89 (0.34–2.32) 0.806 – –
Rectal 3.02 (1.00–9.31) 0.050 – 0.309
T stage 0.90 (0.56–1.45) 0.660 – –
mGPSb 0.95 (0.57–1.61) 0.853 – –
poGPS 3c 2.16 (1.24–3.76) 0.007 2.47 (1.93–3.15) \ 0.001
Overall survival variable Univariate HR (95% CI) p value Multivariate HR (95% CI) p value
Age 1.39 (0.85–2.25) 0.182 – –
Male sex 1.41 (0.66–3.02) 0.373 – –
BMI 0.80 (0.54–1.18) 0.251 – –
ASA 2.19 (1.40–3.42) 0.001 1.96 (1.16–3.33) 0.012
Laparoscopic 0.44 (0.15–1.26) 0.125 – –
Dexamethasone 0.68 (0.28–1.61) 0.378 – –
Rectal 0.64 (0.24–1.70) 0.375 – –
T stage 1.89 (1.07–3.36) 0.029 – 0.165
mGPSb 1.83 (1.18–2.84) 0.007 1.69 (1.08–2.62) 0.020
poGPS 3c 1.39 (0.92–2.12) 0.121 – –
Complication 1.75 (0.77–4.01) 0.183 – –
ASA American Society of Anesthesiologists grade, BMI body mass index, CI confidence interval, HR hazard ratio, OS overall survival, mGPS
modified Glasgow Prognostic Score
aMales = Hb\ 130 g/L, females =\ 120 g/L
b0 = CRP\ 10 mg/L; 1 = CRP C 10 mg/L and albumin C 35 g/L; 2 = CRP C 10 mg/L and albumin\ 35 g/L
c0 = CRP\ 150 mg/L; 1 = CRP C 150 mg/L and albumin C 25 g/L; 2 = CRP C 150 mg/L and albumin\ 25 g/L
S. T. McSorley et al.
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